Product class: Authorized package
Medicinal product class: For human use
Package code: 1814824
Name of medicinal product: BENDAMUSTINE ACCORD
Active substances:
Estonian, English, Latin
ATC code: L01AA09
Dosage form: concentrate for solution for infusion
Route of administration: intravenous use
Strengh: 25mg 1ml
Amount in package: 4ml 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Indolent non-Hodgkin’s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.
Safety features: Yes
Summary of product characteristics (SPC):  (last updated 09 February 2024)
Package information leaflet (PIL): EST  (last updated 17 June 2024)
Labelling:  (last updated 09 February 2024)
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Accord Healthcare B.V. 
Marketing authorization number: 1054622 
Marketing authorization issued on: 07 March 2022 
Marketing authorization expires on: 07 March 2027 
Marketing authorization procedure type: Decentralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: 17 June 2024
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription